Genzyme's Carticel Knee Treatment Drives 56% Revenue Jump In 1998
This article was originally published in The Gray Sheet
Executive Summary
U.S. sales of Genzyme Tissue Repair's Carticel, approved by FDA in August 1997 for treatment of knee cartilage damage, increased 64% in the fourth quarter of 1998 to $2.6 mil., the company notes in reporting preliminary results. Worldwide sales of the autologous cultured chondrocytes product were up 49% to $3.3 mil.
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.